Oncoinvent ASA Reports No New Recurrences in Phase 1 Ovarian Cancer Trial with Radspherin®
Oncoinvent ASA’s Phase 1 ovarian cancer trial shows promising results, with no new recurrences among 10 patients over an 18-month follow-up period, bolstering the potential of its radiopharmaceutical treatment Radspherin.
3 minutes to read